Published in Int J Cancer on February 01, 2000
Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol (2006) 2.91
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res (2010) 2.14
Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol (2012) 1.15
Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites. Br J Cancer (2003) 0.95
Infection and cervical neoplasia: facts and fiction. Int J Clin Exp Pathol (2008) 0.94
Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study. J Clin Oncol (2015) 0.91
Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma. Virol J (2013) 0.77
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J (1995) 7.60
Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem (1992) 3.48
Complete DNA sequence of lymphotropic papovavirus: prototype of a new species of the polyomavirus genus. Virology (1985) 2.53
A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods (2001) 2.15
A viral enhancer element specifically active in human haematopoietic cells. Nature (1985) 1.95
Biochemical engineering of the N-acyl side chain of sialic acid: biological implications. Glycobiology (2001) 1.93
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer (2010) 1.89
UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. Science (1999) 1.88
Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther (1999) 1.73
Somatic diversification of immunoglobulins. Proc Natl Acad Sci U S A (1984) 1.59
Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site. J Virol (1990) 1.52
Cervical intraepithelial neoplasia, cervical carcinoma, and risk for patients with HLA-DQB1*0602,*301,*0303 alleles. Lancet (1993) 1.48
Seropositivity for human papillomavirus and incidence of subsequent squamous cell and basal cell carcinomas of the skin in patients with a previous nonmelanoma skin cancer. Br J Dermatol (2011) 1.45
Biosynthetic modulation of sialic acid-dependent virus-receptor interactions of two primate polyoma viruses. J Biol Chem (1995) 1.40
Marked differences in Betapapillomavirus DNA and antibody prevalence between patients with psoriasis and those with atopic dermatitis. Br J Dermatol (2011) 1.39
Evidence for efficient uptake and incorporation of sialic acid by eukaryotic cells. Eur J Biochem (2001) 1.32
Modeling cancer detection: tumor size as a source of information on unobservable stages of carcinogenesis. Math Biosci (2001) 1.30
Galactan-binding antibodies. Diversity and structure of idiotypes. J Exp Med (1983) 1.30
Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene (2006) 1.29
Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA. J Virol (1991) 1.29
Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol (1998) 1.28
Geographical dependence of sequence variation in the E7 gene of human papillomavirus type 16. J Gen Virol (1992) 1.25
The cell surface receptor is a major determinant restricting the host range of the B-lymphotropic papovavirus. J Virol (1993) 1.14
A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant (2011) 1.13
Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma. Int J Cancer (2000) 1.12
Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine (2004) 1.11
Specific inhibition of human immunodeficiency virus type 1 replication by RNA transcribed in sense and antisense orientation from the 5'-leader/gag region. Biochem Biophys Res Commun (1990) 1.11
Epstein-Barr virus nuclear antigen 2-estrogen receptor fusion proteins transactivate viral and cellular genes and interact with RBP-J kappa in a conditional fashion. Virology (1995) 1.09
Consequences of a subtle sialic acid modification on the murine polyomavirus receptor. J Virol (1997) 1.08
TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. Cancer Lett (2010) 1.05
Serological association of beta and gamma human papillomaviruses with squamous cell carcinoma of the skin. Br J Dermatol (2008) 1.04
Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis. J Virol (1992) 1.02
Characterization of a new human papillomavirus (HPV 41) from disseminated warts and detection of its DNA in some skin carcinomas. Int J Cancer (1988) 1.02
Improving stable transfection efficiency: antioxidants dramatically improve the outgrowth of clones under dominant marker selection. Nucleic Acids Res (1998) 1.01
Electrotransfection of human lymphoid and myeloid cell lines. Nucleic Acids Res (1988) 1.01
Differential sialylation of cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphotropic virus. Glycobiology (1999) 1.00
Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma. Br J Cancer (2013) 1.00
Biosynthesis of N-acetylneuraminic acid in cells lacking UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. Biol Chem (2001) 1.00
Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice. J Exp Med (1993) 0.99
kappa-Chain restriction in anti-galactan antibodies. J Immunol (1982) 0.98
Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet (2000) 0.97
Lack of type-specific concordance between human papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa. J Gen Virol (2011) 0.97
Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract. Blood (1998) 0.96
High resolution mapping of chromosome 6 deletions in cervical cancer. Oncol Rep (1999) 0.96
Human papillomavirus type 16 E5 protein localizes to the Golgi apparatus but does not grossly affect cellular glycosylation. Arch Virol (2000) 0.95
Fast and high-affinity binding of B-lymphotropic papovavirus to human B-lymphoma cell lines. J Virol (1995) 0.94
Regulation of susceptibility and cell surface receptor for the B-lymphotropic papovavirus by N glycosylation. J Virol (1994) 0.94
Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients. J Clin Microbiol (1991) 0.93
Comparative allelotyping of the short arm of human chromosome 3 in epithelial tumors of four different types. FEBS Lett (1999) 0.91
Expression of Epstein-Barr virus nuclear antigen-2 (EBNA2) induces CD21/CR2 on B and T cell lines and shedding of soluble CD21. Eur J Immunol (1995) 0.90
T-cell receptor beta variable region diversity in melanoma metastases after interleukin 2-based immunotherapy. Clin Cancer Res (1996) 0.90
Genome structure and host range restriction of the lymphotropic papovavirus (LPV): identification of a viral lymphocyte specific enhancer element. Curr Top Microbiol Immunol (1984) 0.90
MedB-1, a human tumor cell line derived from a primary mediastinal large B-cell lymphoma. Int J Cancer (2001) 0.89
A monoclonal antibody that defines an idiotope with two subsites in galactan-binding myeloma proteins. J Exp Med (1981) 0.89
Suppression of Burkitt's lymphoma tumorigenicity in nude mice by co-inoculation of EBV-immortalized lymphoblastoid cells. Int J Cancer (1995) 0.89
Risk factors for HIV infection in gynaecological inpatients in Dar es Salaam, Tanzania, 1988-1990. East Afr Med J (1992) 0.88
Tissue restricted expression and chromosomal localization of the YB-1 gene encoding a 42 kD nuclear CCAAT binding protein. Nucleic Acids Res (1992) 0.88
E6/E7 expression of human papillomavirus types in cutaneous squamous cell dysplasia and carcinoma in immunosuppressed organ transplant recipients. Br J Dermatol (2006) 0.88
HPV16 E6 gene variations in invasive cervical squamous cell carcinoma and cancer in situ from Russian patients. Br J Cancer (2001) 0.87
Analysis of intratumoral heterogeneity of chromosome 3p deletions and genetic evidence of polyclonal origin of cervical squamous carcinoma. Mod Pathol (2001) 0.86
Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells. Gene Ther (1997) 0.85
Local growth of a Burkitt's lymphoma versus disseminated invasive growth of the autologous EBV-immortalized lymphoblastoid cells and their somatic cell hybrids in SCID mice. Int J Cancer (1992) 0.85
Risk of seropositivity to multiple oncogenic human papillomavirus types among human immunodeficiency virus-positive and -negative Ugandan women. J Gen Virol (2011) 0.85
Efficient biochemical engineering of cellular sialic acids using an unphysiological sialic acid precursor in cells lacking UDP-N-acetylglucosamine 2-epimerase. FEBS Lett (2001) 0.85
Elongation of the N-acyl side chain of sialic acids in MDCK II cells inhibits influenza A virus infection. Biochem Biophys Res Commun (1998) 0.84
Detection of individual virus-infected cells by filter in situ hybridization. Mol Cell Probes (1988) 0.84
Host range restriction of the lymphotropic papova virus (LPV) in cells of human hematopoietic origin. Haematologica (1988) 0.84
Determination of the binding affinity of different human papillomavirus E7 proteins for the tumour suppressor pRb by a plate-binding assay. J Virol Methods (2001) 0.84
TP53 and EGFR mutations in combination with lifestyle risk factors in tumours of the upper aerodigestive tract from South America. Carcinogenesis (2009) 0.83
Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression. Cancer Res (1990) 0.83
[Juvenile laryngeal papillomatosis--immunisation with the polyvalent vaccine gardasil]. Laryngorhinootologie (2008) 0.83
Hypercross-linked polystyrene and its potentials for liquid chromatography: a mini-review. J Chromatogr A (2002) 0.82
Primary gastric apoptosis-rich T-cell lymphoma co-expressing CD4, CD8, and cytotoxic molecules. Virchows Arch (2000) 0.82
High sensitivity detection of JC-virus DNA in postmortem brain tissue by in situ PCR. J Neurovirol (2000) 0.81
Factors associated with the seroprevalence of 26 cutaneous and two genital human papillomavirus types in organ transplant patients. J Gen Virol (2011) 0.81
Integration of Epstein-Barr virus in Burkitt's lymphoma cells leads to a region of enhanced chromosome instability. Ann Oncol (1997) 0.81
Do cells repair precancerous lesions induced by radiation? Math Biosci (1997) 0.81
Bead-based multiplex genotyping of 58 cutaneous human papillomavirus types. J Clin Microbiol (2011) 0.81
Reliability of PCR-based detection of occult tumour cells: lessons from real-time RT-PCR. Melanoma Res (2001) 0.81
Testing for electrotransfection parameters by use of the fluorescent dye lucifer yellow CH. Anal Biochem (1989) 0.80
Hodgkin's lymphoma-derived tissue serially transplanted into severe combined immunodeficient mice. Blood (1993) 0.80
Structure-function relationships of HIV-1 reverse transcriptase determined using monoclonal antibodies. J Biol Chem (1992) 0.80
Human Golgi beta-galactoside alpha-2,6-sialyltransferase generates a group of sialylated B lymphocyte differentiation antigens. Eur J Immunol (1992) 0.79
Essential role of c-myc in ara-C-induced differentiation of human erythroleukemia cells. Leukemia (1994) 0.79
Integration of Epstein Barr virus near the breakpoint of a translocation 11;19 in a Burkitt's lymphoma cell line. Cancer Genet Cytogenet (1993) 0.78
Down-regulation of integrated Epstein-Barr virus nuclear antigen 1 and 2 genes in a Burkitt lymphoma cell line after somatic cell fusion with autologous EBV-immortalized lymphoblastoid cells. Int J Cancer (1993) 0.78
RGD-mutants of B-lymphotropic polyomavirus capsids specifically bind to alpha(v)beta3 integrin. Arch Virol (2004) 0.78
Antisense RNA-mediated inhibition of the replication of the human immunodeficiency virus type 1. Discussion of critical parameters. Ann N Y Acad Sci (1992) 0.78
First clinical experience with an adjunctive hemoperfusion device designed specifically to remove beta 2-microglobulin in hemodialysis. Contrib Nephrol (2001) 0.77
T cell activation of primed rabbit blood lymphocytes by antigen. Exp Cell Biol (1979) 0.77
Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss. Cancer Res (1998) 0.77
Sequence variation in the E7 gene of human papillomavirus type 18 in tumor and non-tumor patients and antibody response to a conserved seroreactive epitope. Int J Cancer (1993) 0.77
Antibodies against human papillomavirus type 16 and 18 E6 and E7 proteins in cervicovaginal washings and serum of patients with cervical neoplasia. Viral Immunol (2001) 0.77
A stable flank of unstable lymphotropic papovavirus integration sites is associated with a cellular S1 nuclease-sensitive sequence. Virology (1992) 0.77